Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative.

Richard Waldman¹, Mark DeFrancesco², John Feltz³, Daniel Welling⁴, Wade Neiman⁵, Edith Smith⁶, Logan Schneider⁶, Lauren Lenz⁶, Katherine Johansen Taber⁶, Royce Adkins⁶

¹Associates for Women's Medicine, North Syracuse, NY, USA.

²Women's Health Connecticut, Waterbury, CT, USA.

³Lifeline Medical Associates, The Women's Care Source, Morristown, NJ, USA.

⁴Women's Health Connecticut, Manchester, CT, USA.

⁵Associates for Women's Health Services of Central VA, Inc, Lynchburg, VA, USA.

⁶Myriad Genetics Inc, Salt Lake City, UT, USA.

PubMed DOI

Abstract

BACKGROUND: Clinical guidelines recommend hereditary cancer risk assessment (HCRA) to identify candidates for genetic counselling and testing based on personal and family history. Incorporating genetic testing into HCRA improves risk stratification and management. We previously showed that process improvements increase genetic testing completion rates. This study describes outcomes of routine gene…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.